𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapy with interleukin-2 induces the systemic release of phospholipase-A2

✍ Scribed by Gert Jan Wolbink; Caspar Schalkwijk; Joke W. Baars; John Wagstaff; Henk van den Bosch; C. Erik Hack

Publisher
Springer-Verlag
Year
1995
Tongue
English
Weight
661 KB
Volume
41
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Local low-dose interleukin-2 induces sys
Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study
✍ Linda A. Everse; Ingrid B. Renes; Ina M. JΓΌrgenliemk-Schulz; Derk H. Rutgers; Mo πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 58 KB

Tumor recurrence and outgrowth of metastases limit the therapeutical effect of radiotherapy. We have tested whether these problems can be overcome by supplementing radiotherapy with locoregional interleukin-2 (IL-2) treatment. The SL2 lymphoma and the M8013 mammary carcinoma were used. Mice bearing

The systemic complement activation cause
The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation
✍ Francis D. Moore Jr; Deric D. Schoof; Mary Rodrick; Timothy J. Eberlein πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 French βš– 617 KB

Twenty-three cancer patients undergoing therapy with interleukin-2 and lymphokine-activated killer cells were studied for evidence of complement activation and systemic neutrophil activation occurring during the course of therapy. Patient plasma samples demonstrated evidence of marked complement act